CLINICAL EFFECTIVENESS OF THE PREPARATION ENISAMIUM IODIDE IN THE COMPLEX TREATMENT OF ARVI
DOI:
https://doi.org/10.31082/1728-452X-2020-215-216-5-6-32-37Keywords:
acute respiratory viral infections (ARVI), influenza, enisamium iodide (amizone), antiviral therapy, clinical efficacy, safetyAbstract
The list of etiotropic drugs recommended for the treatment of influenza and other acute respiratory viral infections is not very large and requires sufficient justification for rational tactics of their use. In accordance with the WHO strategy for combating influenza and SARS, it is necessary to continue research to study the clinical efficacy of antiviral drugs with a combined effect - etiotropic, pathogenetic and symptomatic. Enisamium iodide is one of such drugs for etiotropic and pathogenetic therapy of ARVI.
Aim. To evaluate the clinical efficacy of the drug enisamium iodide (amizone) in the complex therapy of acute respiratory viral infections (ARVI).
Material and methods. The randomized study included 40 patients who were treated during the epidemic season of influenza and ARVI 2019. Patients of the main group received enisamium iodide along with symptomatic therapy, the control group received only symptomatic therapy. The clinical efficacy of treatment was assessed by the duration of the main clinical symptoms of ARVI, the proportion of patients who developed complications requiring antibiotics. Statistical processing of the obtained data was carried out using the SPSS 12.0.2 software for Windows.
Results and discussion. The results of a randomized study showed the clinical efficacy and safety of amizone (enisamium iodide) in the complex treatment of acute respiratory viral infections of various etiologies, compared with the use of only symptomatic therapy drugs. The duration of fever and the main clinical symptoms of acute respiratory viral infections were statistically significantly less in the study group than in the control group. Accordingly, the proportion of patients whose body temperature returned to normal on days 2–3 of treatment was statistically significantly higher in the group of patients taking enisamium iodide. Complications requiring antibiotic prescription have been reported only in control patients. Also, the drug was well tolerated and there were no side effects during its use.
Conclusions. The results obtained confirmed that enisamium a iodide (amizon) has a good clinical effect in ARVI, reduces the likelihood of complications in patients. The high sensitivity of various respiratory viruses to the drug allows it to be used without etiological decoding of ARVI.
References
Pshenichnaya NY, Bulgakova VA, Volchkova EV, et al. Review of current and future directions of antiviral therapy of influenza and acute respiratory viral infections in Russia. Terapevticheskii arkhiv = Therapeutic archive. 2019;91(11):105-9 (In Russ.)
Spencer S, Nguyen H, Elal AA, et al. Surveillance for Oseltamivir-Resistant Influenza A (H1N1) pdm09 Virus Infections During 2016–2017 and 2017–2018, United States. In Open Forum Infectious Diseases. 2018;5(Suppl. 1):S267.
Kruker AT, Krause M. Oseltamivir-induced delirium. Ther Umsch. 2010 Dec;67(12):613-5. DOI: 10.1024/0040-5930/a000106
Okamoto E. Is oseltamivir (Tamiflu) safe? Re-examining the Tamiflu ado from Japan. Expert Rev Pharmacoecon Outcomes Res. 2010 Feb;10(1):17-24. DOI: 10.1586/erp.09.70
Ono H, Okamura M, Fukushima A. Similarity of Clinically Significant Neuropsychiatric Adverse Reactions Listed in Package Inserts between the Anti-influenza Drugs Oseltamivir and Amantadine (Possibility Attributable to Common Pharmacological Effects. Yakugaku Zasshi. 2018 Sep 1;138(9):1201-15. DOI: 10.1248/yakushi.18-00022
Ershov FI, Kiselev OI. Interferons and their inducers (from molecules to drugs). M.:GEOTAR-Media; 2005. 368 р.
Ponezheva ZhB, Kupchenko AN, Mannanova IV, Gorelov AV. Interferons and Antiviral Immunity. Effektivnaia farmakoterapiia = Effective pharmacotherapy. 2018;1(14):14-21 (In Russ.)
Global influenza strategy 2019-2030. Geneva: World Health Organization, 2019. Available from: https://apps.who.int/iris/bitstream/handle/10665/311184/9789241515320-eng.pdf?ua=1 [Accessed 20.07.2019]
Casanova JL, Abel L. The human model: a genetic dissection of immunity to infection in natural conditions. Nat. Rev. Immunol. 2004;4(1):55–66. DOI: 10.1038/nri1264
Boltz D, Peng X, Muzzio M, et al. Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells. Antivir Chem Chemother. 2018;26:2040206618811416. DOI: 10.1177/2040206618811416
Frolov AF, Frolov VM, Bukhtiarova TA, Danilenko VF. Clinical aspects of the use of Amizon. Ukrainian Medical Journal. 2004;1(39):69–74
Keynan Y., Card CM. Mc Laren PJ, et al. The role of regulatory T-cells in chronic and acute viral infections. Clin. Infect. Dis. 2008;46(7):1046–1052. DOI: 10.1086/529379
Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010;11(5):373–384. DOI: 10.1038/ni.1863
Ramos I, Fernandez-Sesma A. Modulating the innate immune response to influenza A virus: potential therapeutic use of anti-inflammatory drugs. Frontiers in immunology. 2015;(6):361. DOI: 10.3389/fimmu.2015.00361
Isakov VA, Ohapkina EA, Evgrafov VD. Jeffektivnost’ amizona v terapii i profilaktike ORVI. Medicinskij forum = Medical Forum. 2015;1(2):2-9 (In Russ.)
Melnikova TI, Deeva EG, Amosova IV, et al. Clinical efficacy of Amizon in the treatment of influenza and other acute respiratory viral infections. Zdorove Ukrainy = Health Ukraine. 2013;17:40–41 (In Russ.)
Paevskaya OA, Zuevskaya SN, Nikiforov VV, Belaya OF, Kolaeva NV, Nemilostiva EA, Kanshina NN, Turkadze KA. Possibilities of etiotropic therapy in reducing the risks of developing a severe or complicated course of acute respiratory viral infections and influenza. RMZh = RMZh. 2019;1(II):77-80 (In Russ.).
